Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection

Ewaisha, Radwa; Bahey-El-Din, Mohammed; Mossallam, Shereen F.; Amer, Eglal I.; Abou-Shleib, Hamida; Khalil, Amal M

doi:10.1016/j.exppara.2014.07.010

Cited by 19 publications

(19 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We recently investigated the potential vaccine efficacy of Sm14 and Sm29 mixture for protection against schistosomiasis in murine model [ 19 ]. When the two antigens were combined, they could elicit good protection where 31.2% and 40.3% reduction of adult worm burden were attained in mice immunized with the unadjuvanted or poly(I:C)-adjuvanted combination, respectively.…”

Section: Introductionmentioning

confidence: 99%

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

et al. 2015

Self Cite

View full text Add to dashboard Cite

BackgroundSchistosoma mansoni infection represents a major cause of morbidity and mortality in many areas of the developing world. Effective vaccines against schistosomiasis are not available and disease management relies mainly on treatment with the anthelmintic drug praziquantel. Several promising schistosomal antigens have been evaluated for vaccine efficacy such as Sm14, Sm29 and tetraspanins. However, most investigators examine these promising antigens in animal models individually rather than in properly adjuvanted antigen combinations.MethodsIn the present study, we made a recombinant fusion protein comprised of the promising schistosomal antigens Sm14 and Sm29. The fusion protein, FSm14/29, was administered to Swiss albino mice either unadjuvanted or adjuvanted with polyinosinic-polycytidylic acid adjuvant, poly(I:C). Mice were challenged with S. mansoni cercariae and different parasitological/immunological parameters were assessed seven weeks post-challenge. Data were analyzed using the ANOVA test with post-hoc Tukey-Kramer test.ResultsMice pre-immunized with unadjuvanted or poly(I:C)-adjuvanted fusion protein showed reduction of adult worm burden of 44.7 and 48.4%, respectively. In addition, significant reduction of tissue egg burdens was observed in mice immunized with the fusion protein when compared with the infected saline/adjuvant negative control groups and groups immunized with the individual Sm14 and Sm29 antigens. Light microscope and scanning electron microscope (SEM) investigation of adult worms recovered from FSm14/29-immunized mice revealed appreciable morphological damage and tegumental deformities. Histopathological examination of liver sections of immunized mice demonstrated reduced granulomatous and inflammatory reactions when compared with infected unvaccinated mice or mice immunized with the individual Sm14 and Sm29 antigens.ConclusionThe findings presented in this study highlight the importance of the fusion protein FSm14/29 as a potential vaccine candidate that is worthy of further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings are explained by Etewa et al, (15) who stated that combining different antigens provides augmentation of the protective immunity compared to each component administered individually. On the other hand, a lower percentage in the reduction of adult worms (40.3%) was detected by Ewaisha et al, (51) on using a multi-antigen vaccine composed of recombinant Sm14 and a truncated form of Sm29, designated TrSm29, in the presence of the immunoadjuvant poly (I:C). Accordingly, the researchers concluded that using multi-antigen vaccines is a more effective approach to fulfill enhanced protection against schistosomiasis than giving each component individually.…”

Section: Discussionmentioning

confidence: 92%

A potential prophylactic strategy of anti-schistosomal immunization using nanotechnology in murine models

Etewa

Al-Hoot

Sharaf

et al. 2018

Parasitologists United Journal

View full text Add to dashboard Cite

Background: The emergence of chemotherapy resistant schistosomes necessitates finding new prophylaxis strategies based on immunization by using a modified vaccine candidate. Objective: To assess the potential of an anti-schistosomal vaccine modified by nanotechnology. Material and Methods: Soluble adult worm antigen preparation (SWAP) either crude or/and loaded on chitosan nanoparticles (CSNPs) were used. The anti-schistosomal impact was assessed in terms of stools egg count, worm burden and ultrastructural study of juvenile and adult schistosomes. Results: Chitosan nanoparticles potentiated SWAP efficacy to exceed the impact of crude SWAP. The combination of SWAP loaded on CSNPs and crude SWAP showed the best immunization effects regarding adult worm number and fecundity, as well as morphological and tegumental distortion of juvenile than adult stages. Conclusion: Modified SWAP on CSNPs gave better results in anti-schistosome immunization than crude SWAP. Immunization by combining different antigens gave the best results.

show abstract

“…The Pichia produced SM14 antigen immunized with GLA adjuvant induced a broad IgG response with no adverse effects outside of self-limited reactions at the site of injection [34]. The Sm14 antigen in conjunction with the Sm29 antigen has been reported to provide significant protection against S. mansoni in mice [35]. In this latter case, the antigen prepared from recombinant E. coli carries an endotoxin burden as well as the complications from purification of the antigen from the host cells.…”

Section: Characterization Of Sm14 Expressed By P Pastorismentioning

confidence: 98%

Process development for production and purification of the Schistosoma mansoni Sm14 antigen

Damasceno

Ritter

Batt

2017

Protein Expression and Purification

View full text Add to dashboard Cite

Combination of the two schistosomal antigens Sm14 and Sm29 elicits significant protection against experimental Schistosoma mansoni infection

Cited by 19 publications

References 41 publications

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

Fusion protein comprised of the two schistosomal antigens, Sm14 and Sm29, provides significant protection against Schistosoma mansoni in murine infection model

A potential prophylactic strategy of anti-schistosomal immunization using nanotechnology in murine models

Process development for production and purification of the Schistosoma mansoni Sm14 antigen

Contact Info

Product

Resources

About